Peptide education
IGF-1 DES
Cut the first three amino acids off IGF-1 and you get IGF-1 DES, a 67-amino-acid fragment formally named des(1-3) IGF-I. Losing that Gly-Pro-Glu segment frees the molecule from most IGF binding proteins, so in cell and rodent experiments it activates IGF-1 receptors more strongly than the full-length hormone, which is the real origin of the "ten times stronger" line. Vendors and bodybuilding blogs turn that lab potency into a product story: inject it into the muscle you just trained and get local growth. No human trial, human pharmacokinetic study, or approved indication exists for any of it.
IGF-1 DES outperforms real IGF-1 in dishes and GH-deficient mice, and has zero human studies behind the site-growth claims it sells on. A 20-to-30-minute half-life makes the pitch sound precise; it does not make it tested.
Overview
Quick answer
IGF-1 DES is not native IGF-1, not mecasermin, and not IGF-1 LR3. Mecasermin is the approved full-length IGF-1 drug for rare severe primary IGF-1 deficiency. IGF-1 DES is an unapproved research analog with no human trial found, no approved label, and no verified clinical protocol.
What is IGF-1 DES?
A 67-amino-acid IGF-1 analog missing the N-terminal Gly-Pro-Glu tripeptide. The truncation drops its affinity for IGF binding proteins, so more free peptide reaches IGF-1 receptors in lab systems. Think of it as a sharper, shorter-lived IGF-1, not a drug with its own evidence base.
Why is it discussed?
Because preclinical papers show unusually strong growth-factor activity, and the market translated that into a "site-specific growth" product: inject near a lagging muscle after training, grow that muscle. The preclinical potency is documented. The local hypertrophy in a living human is not.
What evidence and reported-use patterns are available?
Rodent work used 3 to 30 micrograms per day; in GH-deficient lit/lit mice, 3 micrograms of DES increased organ weights where the same dose of native IGF-1 did not. Bodybuilding practice is described as 50 to 100 mcg a day split into trained muscles on training days for 4 to 6 weeks, reported use, not a studied regimen. Hypoglycemia, misdirected tissue growth, and microgram measurement error ride along, unquantified in people.
Has local muscle growth been shown in people?
No. The pitch leans on reduced binding-protein attachment and a short reported half-life, which makes local action sound plausible. There is no controlled human study, and not even a decent case series, showing selective hypertrophy at an injection site.
How reliable are forum amount claims?
About as reliable as the vials, which is to say unverified. Forum numbers arrive without confirmed product identity, concentration, sterility, or outcome tracking, and the compound has no human dose-response data to check them against.
Reported practice
Commonly reported protocol
Community performance protocols. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
Primary literature describes des(1-3) IGF-I as a shortened IGF-1 variant with markedly reduced binding to IGF binding proteins and stronger growth-promoting activity in several lab models.
No published controlled human trial, human pharmacokinetic study, or approved clinical indication was found for IGF-1 DES.
Vendor and protocol-blog sources present IGF-1 DES as a short-acting, injection-site growth peptide, but human evidence for that result was not found.
Hypoglycemia, abnormal tissue growth, tumor-promotion concerns, injection problems, and product-quality failures are inferred from IGF biology and gray-market use rather than measured in a human IGF-1 DES safety program.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| IGF-1 DES produces targeted muscle growth where it is injected. | No controlled human study of site-injected IGF-1 DES or case series showing local hypertrophy in people was found. | Market copy leans on reduced IGFBP binding, strong IGF-1 receptor signaling, and a short reported half-life. Those facts make a local-use theory plausible enough to sell, but they do not show that injected tissue grows selectively in living humans. | Vendor pages and bodybuilding blogs commonly describe post-workout or site-specific injections for lagging muscles, usually without controlled comparisons, verified products, or objective imaging. | "Local growth" is the market phrase. Human site-specific hypertrophy evidence was not found. |
| IGF-1 DES is about 10 times stronger than native IGF-1. | No human potency data found. The 10-fold language comes from preclinical comparisons, not human outcomes. | Cell and animal work described IGF-1 DES as much more active than native IGF-1 in several growth assays, partly because it binds IGF binding proteins much less. | Vendors repeat the 10-times-stronger line as a selling point for bodybuilding and recovery use, often without explaining that the evidence is preclinical. | Reasonable only as a lab-model potency statement. It is not a human dose conversion or expected muscle-gain result. |
| IGF-1 DES can build muscle, cause hyperplasia, or speed recovery. | No published human muscle, performance, injury-recovery, or body recomposition trial was found for IGF-1 DES. | IGF-1 receptor activation can feed PI3K-Akt-mTOR signaling, protein synthesis, and muscle-cell growth pathways. Rodent and cell findings support growth-factor activity, not a measured bodybuilder outcome. | Protocol blogs and forum-style bodybuilding discussion attach IGF-1 DES to lagging-muscle work, pumps, recovery, satellite-cell activation, and short cycles around training. | Mechanistically understandable and common in bodybuilding discussion, but still built mostly from preclinical work and anecdotes. |
| The short half-life makes it safer than longer-acting IGF analogs. | No human safety comparison found between IGF-1 DES, native IGF-1, and IGF-1 LR3. | A shorter signal may reduce exposure time, but high free receptor activity can still matter, especially when dose, concentration, and product identity are uncontrolled. | Online discussions often frame the short 20-to-30-minute half-life as a reason to use it around training or injection sites. That timing logic does not measure hypoglycemia, unwanted tissue growth, local reactions, or product risk. | A short half-life is not the same as lower risk. |
| Vendor COAs make IGF-1 DES research vials reliable. | Human efficacy and safety evidence does not answer whether a current vendor vial is correctly made. That is a manufacturing and testing question. | For an injectable peptide, identity, sequence, concentration after reconstitution, sterility, endotoxin, degradation, storage, and shipping conditions all matter. A narrow HPLC purity number still leaves sterility, endotoxin, concentration, degradation, and shipping questions open. | Vendor pages describe HPLC purity, third-party testing, research-use disclaimers, and freeze-dried vial storage. Reported testing concerns also include impurities and degradation products in research peptide samples. | A COA can be a clue, but pharmaceutical-grade sterility, correct concentration, and clinical comparability need more than a narrow purity document. |
Bottom line
Main takeaway
IGF-1 DES is a lab-potent fragment of IGF-1 sold on a local-growth theory that has never been tested in humans.
DES, LR3, native IGF-1, and mecasermin are four molecules with four different evidence files. DES has the emptiest one: structure plus rodent potency, nothing human.
Ballard 1996 and Gillespie 1990 tell you what the analog does in models; vendor pages and protocol blogs tell you how it is sold. There is no human tier in between, so do not let either side imply one.
Identity
What it is
Native IGF-1 is a 70-amino-acid growth factor that circulates mostly bound to IGF binding proteins. IGF-1 DES deletes the first three residues, Gly-Pro-Glu, producing a 67-amino-acid fragment that slips most of that binding.
In assays, the result is striking: DES outperforms native IGF-1 in cell-proliferation models, and in GH-deficient mice 3 micrograms a day produced organ growth that the same dose of full-length IGF-1 could not. That comparison is the entire factual basis of "ten times stronger." It is a lab potency ratio, not a human dose conversion and not a muscle-gain forecast.
The short half-life gets marketed as a safety feature and a targeting feature at once: inject post-workout, act locally, clear fast. None of that chain has been demonstrated. Free receptor activity is free receptor activity, and a compound this potent in models is exactly the kind where hypoglycemia and misdirected growth deserve human data rather than inference.
Supply is the final problem. Research vials with purity percentages do not answer sterility, endotoxin, or degradation, and microgram dosing makes reconstitution and syringe math a real exposure variable.
How people talk about it online
Vendor pages lead with the reduced IGFBP binding, the potency multiples, the reported 20-to-30-minute half-life, and "local" or "site" language, usually beside a research-use disclaimer. That combination is aimed squarely at bodybuilding demand.
Protocol blogs describe post-workout injections into lagging muscles at small microgram amounts. These write-ups are the closest thing to use data that exists for DES, and they come with no verified product, no controls, and no follow-up.
Forums position DES as the shorter, sharper cousin of LR3. The comparison is memorable and hides the shared problem: neither molecule has human pharmacokinetics, human outcomes, or verified product identity behind the talk.
Use context
Routes, doses, and cycle patterns
IGF-1 DES has no approved human label and no human study regimen found. Amount details come from cell culture, rodent studies, and online bodybuilding or vendor sources. Microgram-per-day rodent data cannot be turned into a post-workout human injection schedule.
Human studies and product labels
No approved human label
- Purpose
- Regulatory and clinical-use status
- Context
- Approved-drug comparison and no-human-trial finding
- Route
- No approved route for IGF-1 DES
- Amount
- No approved labeled amount
- Frequency
- No approved labeled frequency
- Duration
- No approved labeled duration
Mecasermin is the approved full-length IGF-1 drug for rare severe primary IGF-1 deficiency. IGF-1 DES is not the same drug and has no approved dosing label found.
Growth-hormone-deficient mouse dosing
- Purpose
- Preclinical growth-factor activity
- Context
- Rodent study
- Route
- Injection in animal model
- Amount
- 3 to 30 micrograms per day
- Frequency
- Daily in the reported mouse model
- Duration
- Study-specific animal experiment
Gillespie 1990 is described as using 3 micrograms per day of IGF-1 DES and increasing organ weights in lit/lit mice when the same dose of native IGF-1 lacked the same effect. That supports potency in a disease-model animal study, not a human bodybuilding regimen.
Cell-culture potency comparisons
- Purpose
- Receptor signaling and growth assays
- Context
- In vitro studies
- Route
- Cell culture
- Amount
- Reported as concentrations such as 1 to 100 ng/mL in lab assays
- Frequency
- Experimental exposure, not a dosing schedule
- Duration
- Assay-specific
Cell-culture work explains why IGF-1 DES is described as highly potent. It leaves human injection amount, frequency, cycle length, and safety unanswered.
Animal and analog pharmacology context
- Purpose
- Nonhuman comparison with IGF variants
- Context
- Nonhuman pharmacology and analog literature
- Route
- Study-specific nonhuman routes
- Amount
- Study-specific
- Frequency
- Study-specific
- Duration
- Study-specific
The cited nonhuman sources include pig and marmoset pharmacology and recombinant-characterization papers for des(1-3) IGF-I. Those help define the analog, not human clinical outcomes.
Real-world discussion
Community performance protocols
- Purpose
- Localized muscle growth discussion
- Context
- Forums, vendors, and protocol blogs
- Route
- Subcutaneous injection
- Amount
- Community use is usually described as 50 to 100 mcg per day, split bilaterally into the trained muscle groups before or after training.
- Frequency
- Once daily on training days in most descriptions
- Duration
- Usually described as short cycles of 4 to 6 weeks
IGF-1 DES is treated in community discussion as the shorter-acting, more potent counterpart to LR3, with the same hypoglycemia caution and no human outcome data for physique use. Shared here as context, not instruction.
What varies
- Goal: muscle gain, site growth, fat loss, and recovery claims come from different sources; none provides controlled human evidence for IGF-1 DES.
- Route: online use usually assumes injection, which makes sterility, endotoxin, reconstitution, concentration, storage, and local reaction risk central.
- Amount: rodent microgram-per-day dosing cannot be converted into bodybuilding microgram-per-injection advice.
- Frequency: the short half-life is used to justify post-workout timing, but no reviewed human pharmacokinetic study confirms a safe or effective schedule.
- Cycle length: community material most often describes short cycles of 4 to 6 weeks, and those cycles are not clinical regimens.
Human data
Human evidence
There is none to summarize. No controlled human trial, human pharmacokinetic study, or human safety program has been published for IGF-1 DES in any application: muscle growth, fat loss, recovery, or local injection. The human-use conversation is vendor copy, protocol blogs, and forum reports laid over cell and rodent biology. Benefit and risk are both unmeasured in people, so the confident schedules circulating online are extrapolation from animals, not measurement.
Evidence maturity
IGF-1 DES is potent in cell and rodent models but has no human trials at all; the muscle-growth market is built on preclinical data and anecdotes.
Research defined des(1-3) IGF-I as a truncated IGF-1 analog with markedly reduced binding to IGF binding proteins.
Cell assays and growth-hormone-deficient mice showed stronger growth effects than native IGF-1 at matched doses.
No controlled human trial, human pharmacokinetic study, or approved indication has been found for IGF-1 DES.
Site-growth and post-workout claims come from vendors and protocol blogs, with hypoglycemia and product-quality risks unquantified in people.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| No published human IGF-1 DES trial found | People considering IGF-1 DES for muscle, recovery, fat loss, or local growth | Evidence gap | Unapproved research analog and gray-market vials | No controlled human studies, published human dosing protocol, or approved clinical indication were found for IGF-1 DES. | That absence leaves both benefit and risk uncertain. | weak |
| Ballard et al. truncated IGF-1 characterization | Cell and nonhuman experimental models | Preclinical characterization and growth assays | Research peptide / experimental analog | Ballard 1996 is described as showing des(1-3) IGF-I as more potent than native IGF-1 in cell proliferation and growth-related assays, with reduced binding to IGF binding proteins. | Cell and animal potency cannot be converted into human injection amount, duration, expected muscle gain, or safety. | preclinical |
| Gillespie et al. GH-deficient mouse comparison | Growth-hormone-deficient lit/lit mice | Rodent comparative study | Experimental IGF-1 DES compared with native IGF-1 | Gillespie 1990 is described as using 3 micrograms per day of IGF-1 DES and increasing body length or organ weights in the mouse model where the same dose of native IGF-1 lacked the same effect. | A GH-deficient mouse model cannot answer benefit, dosing, or safety for healthy adults, athletes, or injured tissue. | preclinical |
| Bodybuilding protocol-blog and vendor claims | Fitness and gray-market audiences | Anecdotal and commercial material | Research-use vials and non-approved online protocols | Sources discuss local injections, post-workout timing, small microgram amount ranges, short half-life, potency, hyperplasia, recovery, and fat-loss claims. | These sources do not provide controlled outcomes, verified vial identity, adverse-event follow-up, or a comparison group. | anecdotal |
Cautions
Safety and unknowns
- Hypoglycemia is a plausible concern because IGF-1 signaling overlaps with insulin-like metabolic effects; no IGF-1 DES human safety study was found to quantify the risk.
- Abnormal tissue growth, organ growth, joint symptoms, and acromegaly-like concerns are biologically plausible when IGF signaling is pushed without clinical monitoring.
- Cancer and tumor-promotion risk is a serious open question. IGF-1 receptor signaling is mitogenic, and no human DES safety data were found in people with malignancy risk.
- Injection risks include local irritation, infection, abscess risk, endotoxin exposure, concentration errors after reconstitution, and dosing mistakes with microgram amounts.
- Pregnancy, pediatric, endocrine, diabetes, cardiovascular, and long-term exposure risks are not characterized for IGF-1 DES.
Product quality
A vial label is only a starting point
IGF-1 DES is sold online as research material, not as an FDA-reviewed injectable drug product with approved labeling and release controls.
Vendor COAs usually focus on identity or HPLC purity. Sterility, endotoxin control, accurate concentration after reconstitution, shipping stability, and degradation products need their own documentation.
The peptide is handled in microgram amounts, so vial concentration, dilution math, adsorption, storage, and syringe measurement errors can materially change exposure.
Identity
IGF-1 DES, IGF-1 LR3, native IGF-1, and mecasermin are different molecules. A vendor label has to match the actual sequence.
Sterility and endotoxin
Injectable-style use adds risks that a simple purity percentage does not answer.
Concentration
Gray-market protocols discuss microgram amounts, so reconstitution and syringe math can easily produce large relative errors.
Stability
Lyophilized peptide storage, warm shipping, repeated freeze-thaw, and time in solution may affect potency and degradation.
Mechanism
How it is proposed to work
IGF-1 DES works like a more freely available IGF-1 signal in lab systems. By removing the first three amino acids, the peptide binds IGF binding proteins much less and can more readily activate IGF-1 receptors, which trigger growth and survival pathways inside cells.
IGF-1 receptor activation feeds PI3K-Akt-mTOR signaling, a pathway tied to protein synthesis, cell growth, and reduced protein breakdown.
Lower binding to IGFBP-1, IGFBP-2, and IGFBP-4 means less of the peptide is sequestered outside the receptor interaction. That is the central biochemical reason DES can look more potent than native IGF-1 in assays.
The reported short half-life is used by marketers to argue for local action, but short exposure alone leaves tissue selectivity unproved after injection.
IGF biology can support tissue growth in the right setting, but the same biology creates safety questions around blood glucose, unwanted tissue growth, and cancer-related signaling.
FAQ
Common questions
How is IGF-1 DES different from IGF-1 LR3?
DES lacks the first three amino acids, which reduces binding-protein attachment and makes it shorter-acting and more locally potent. Community use reflects that: pre-workout bilateral injections rather than LR3's once-daily pattern.
What do community protocols look like?
Commonly 50 to 100 mcg per day, split into the trained muscle groups around workouts, in 4 to 6 week cycles.
Does IGF-1 DES have human evidence?
None. Like LR3, the modification popular in bodybuilding has never been studied in humans, and hypoglycemia is the shared mechanism risk.
Details
Technical details
Sources
References
- 1.
Ballard 1996 analog paper. Ballard 1996
IGF-1 DES background and mechanism.
- 2.
Gillespie mouse study. Gillespie 1990
IGF-1 DES background and mechanism.
- 3.
Alpha Carbon listing. Alpha Carbon Labs vendor page
Vendor-market context.
- 4.
Loti Labs blog. Loti Labs blog
Online-use context.
- 5.
Jay Campbell blog. Jay Campbell blog
Online-use context.
- 6.
Vendor safety warnings. Vendor safety warnings
Product-quality warning context.
- 7.
Palmetto blog. Palmetto Peptides blog
Online-use context.
- 8.
SwissChems COA. SwissChems vendor COA
COA and vendor-market context.
- 9.
Bio-Techne listing. Bio-Techne product listing
Research-material context.
- 10.
Human-trial gap search. Targeted literature and trial-registry review for IGF-1 DES human studies.
Documents that no controlled human trial, human pharmacokinetic study, or approved clinical indication was found.
- 11.
PMID 9415072. PMID 9415072
Mechanistic context.
- 12.
PMID 1883485. PMID 1883485
Mechanistic context.
- 13.
Degradation warning. Research peptide degradation warning
Stability and handling context.